Co-IP further validated that rhENO1 (1 μg/mL) increased binding between ENO1 and TLR4 in GBM cells (Fig. 4E, F), and immunofluorescence (IF) assays demonstrated their co-localization in GBM cells and tissues (Fig. 4G). This evidence concerns the gene ENO1 and glioblastoma.